Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Ozempic Maker’s Stock Plunges 20% After Profit Warning

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.

Eshe Nelson
Author: Eshe Nelson

Written by

Eshe Nelson

in

Appointments and Executive Changes, Drugs (Pharmaceuticals), GLP-1 RAs (Drug), Novo Nordisk A/S, Ozempic (Drug), Stocks and Bonds
←In The Chair With: Taraji P. Henson’s Makeup Artist Keita Moore
Morton Mintz, Muckraking Crusader for Consumers, Dies at 103→

More posts

  • Protesters, leaders push back against DHS over Newark detention facility conditions

  • Goldman and Lander spar hard over Israel

  • Snowflake climbs after Q1 results top expectations, guidance gets a boost

  • Synopsys drops despite better than expected Q2 results, big boost to full-year guidance

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube